Pfizer has reached an agreement with the Trump Administration aimed at reducing the cost of prescription medicines for American patients. The deal, announced at the White House, introduces a new government purchasing platform, TrumpRx.gov, through which patients in the U.S. will be able to buy a wide range of Pfizer treatments at lower prices.
The company says most primary care drugs and selected speciality medicines will be offered at an average discount of 50%, with some reduced by as much as 85%.
Another key element of the agreement is Pfizer’s commitment to price newly launched medicines in the U.S. at the same level as in other developed countries.
In return, the company will benefit from tariff protections and regulatory clarity, conditions that Pfizer argues will allow it to expand U.S. manufacturing and direct an additional $70 billion into research and development over the next few years.
Pressure from the White House
The agreement follows months of political pressure. President Donald Trump has long criticised pharmaceutical companies for charging U.S. patients far more than those in Europe and other developed markets.
Speaking at the White House, he acknowledged that while the deal should bring American prices down, it could lead to higher prices abroad. He described this outcome as “fair,” arguing that U.S. families should no longer shoulder a disproportionate share of the global cost of innovation.
The global price balance
This raises questions for European countries, where drug prices are often set or negotiated by governments and are considerably lower than in the U.S. A Health and Human Services report released last year found that Americans pay nearly three times as much for medicines as patients in peer countries.
If companies shift their global pricing strategies to narrow this gap, Europe could face upward pressure on medicine costs. That would challenge health systems already grappling with tight budgets and growing demand for new treatments.
Will patients actually benefit?
In the U.S., analysts warn that lower list prices do not always translate into savings for patients. The final cost depends on a complex chain of insurers, pharmacies, and pharmacy benefit managers, meaning discounts may not fully reach consumers.
For Pfizer, the deal secures a stable business environment and the opportunity to focus on future therapies in oncology, obesity, vaccines, and immunology. For U.S. patients, the promise is lower costs at the pharmacy counter, though the real impact remains to be seen. For Europe, however, the question is whether this American deal will ultimately make medicines more expensive across the Atlantic.
01.10.2025.
